GT201200293A - Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs) - Google Patents

Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)

Info

Publication number
GT201200293A
GT201200293A GT201200293A GT201200293A GT201200293A GT 201200293 A GT201200293 A GT 201200293A GT 201200293 A GT201200293 A GT 201200293A GT 201200293 A GT201200293 A GT 201200293A GT 201200293 A GT201200293 A GT 201200293A
Authority
GT
Guatemala
Prior art keywords
treatment
fxs
predictive markers
useful predictive
fragile syndrome
Prior art date
Application number
GT201200293A
Other languages
English (en)
Inventor
Gomez-Mancilla Baltazar
Paulding Charles
Meyer Joanne
Johns Donald
He Yunsheng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44121075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200293(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of GT201200293A publication Critical patent/GT201200293A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A MARCADORES PREDICTIVOS ÚTILES PARA PREDECIR SÍ UN INDIVIDUO QUE TENGA EL SÍNDROME X FRÁGIL RESPONDERÁ CLÍNICAMENTE AL TRATAMIENTO CON UN AGENTE TERAPÉUTICO PARTICULAR, BASADA EN EL HALLAZGO DE QUE SE PUEDEN UTILIZAR BIOMARCADORES PARTICULARES PARA SELECCIONAR AQUELLOS INDIVIDUOS QUE PADEZCAN DICHO SÍNDROME
GT201200293A 2010-04-30 2012-10-30 Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs) GT201200293A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33029910P 2010-04-30 2010-04-30
US37919710P 2010-09-01 2010-09-01

Publications (1)

Publication Number Publication Date
GT201200293A true GT201200293A (es) 2014-06-09

Family

ID=44121075

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200293A GT201200293A (es) 2010-04-30 2012-10-30 Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)

Country Status (21)

Country Link
US (1) US20130052644A1 (es)
EP (1) EP2563934A1 (es)
JP (1) JP2013524840A (es)
KR (1) KR20130100906A (es)
CN (1) CN102869791A (es)
AU (1) AU2011245372A1 (es)
BR (1) BR112012027816A2 (es)
CA (1) CA2797854A1 (es)
CL (1) CL2012003027A1 (es)
EC (1) ECSP12012317A (es)
GT (1) GT201200293A (es)
IL (1) IL222534A0 (es)
MA (1) MA34263B1 (es)
MX (1) MX2012012615A (es)
PE (1) PE20130213A1 (es)
RU (1) RU2012151273A (es)
SG (1) SG184458A1 (es)
TN (1) TN2012000485A1 (es)
TW (1) TW201142293A (es)
WO (1) WO2011137206A1 (es)
ZA (1) ZA201207481B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CA3162352A1 (en) 2010-10-01 2012-04-05 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US20130274294A1 (en) * 2010-12-20 2013-10-17 David Carcache 4-(Hetero)Aryl-Ethynyl-Octahydro-Indole-1-Esters
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
LT2791160T (lt) 2011-12-16 2022-06-10 Modernatx, Inc. Modifikuotos mrnr sudėtys
WO2013131981A1 (en) 2012-03-08 2013-09-12 Novartis Ag Predictive markers useful in the diagnosis and treatment of fragile x syndrome (fxs)
CA2868996A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014152600A2 (en) * 2013-03-15 2014-09-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Measurement of cellular fmrp levels for high throughput drug screening and diagnosis of fragile x syndrome
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
CA2926645C (en) * 2013-10-14 2022-10-25 Indiana University Research And Technology Corporation Use of acamprosate to modulate erk 1/2 activation in animal models for fxs and asd and individuals diagnosed with fxs and asd
CN103981253A (zh) * 2014-03-27 2014-08-13 江苏佰龄全基因生物医学技术有限公司 一种用于检测脆性x染色体综合征的cgg重复数及agg插入信息的pcr试剂盒
EP4244631A1 (en) * 2020-11-13 2023-09-20 Children's Hospital Medical Center Refined uses of gabaa receptor modulators in treatment of fragile x syndrome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6143504A (en) * 1998-10-27 2000-11-07 Arch Development Corporation Methods and compositions for the diagnosis of fragile X syndrome
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
CN1894241A (zh) 2002-08-09 2007-01-10 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
JP4453297B2 (ja) 2003-05-27 2010-04-21 トヨタ自動車株式会社 車両用遊星歯車式多段変速機
TW200801005A (en) 2005-08-15 2008-01-01 Astrazeneca Ab Acetylenic piperazines as metabotropic glutamate receptor antagonists
US20090042195A1 (en) * 2005-10-07 2009-02-12 Bradford Coffee Methods and systems for screening for and diagnosing dna methylation associated abnormalities and sex chromosome aneuploidies
US7855053B2 (en) * 2006-07-19 2010-12-21 The Regents Of The University Of California Methods for detecting the presence of expanded CGG repeats in the FMR1 gene 5′ untranslated region
EA201100297A1 (ru) 2008-08-04 2011-10-31 Новартис Аг Биотесты на белок polyq
US20100248239A1 (en) * 2009-03-24 2010-09-30 Mayo Foundation For Medical Education And Research Methods and materials for detecting fragile x mutations

Also Published As

Publication number Publication date
TW201142293A (en) 2011-12-01
SG184458A1 (en) 2012-11-29
RU2012151273A (ru) 2014-06-10
US20130052644A1 (en) 2013-02-28
MA34263B1 (fr) 2013-05-02
CL2012003027A1 (es) 2014-02-14
CA2797854A1 (en) 2011-11-03
ECSP12012317A (es) 2013-01-31
BR112012027816A2 (pt) 2017-08-08
MX2012012615A (es) 2012-12-17
ZA201207481B (en) 2013-06-26
CN102869791A (zh) 2013-01-09
WO2011137206A1 (en) 2011-11-03
TN2012000485A1 (en) 2014-04-01
JP2013524840A (ja) 2013-06-20
PE20130213A1 (es) 2013-03-19
IL222534A0 (en) 2012-12-31
EP2563934A1 (en) 2013-03-06
AU2011245372A1 (en) 2012-11-29
KR20130100906A (ko) 2013-09-12

Similar Documents

Publication Publication Date Title
GT201200293A (es) Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs)
CU20140025A7 (es) Pirimidinas anilladas sustituidas
BR112012009135A2 (pt) composição polímera termoplástica
BR112012029917A2 (pt) composições de nanotransportador com adjuvante desacoplado
BR112013030599A2 (pt) núcleo absorvente para artigos absorventes descartáveis
BR112015001101A2 (pt) formas cristalinas de um inibidor de prolil hidroxilase
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
BR112012019529A2 (pt) inibidores de d-nitrosoglutationa redutase
BR112012032033A2 (pt) novas formas de dosagem de libertação modificada de inibidor de xantina oxidorredutase ou inibidores de xantina oxidase
TWD158887S (zh) 粉餅盒
GT201200284A (es) Composición farmacéutica
BR112012016894A2 (pt) lactobacilos com ação antioxidante.
BR112013011259A2 (pt) condições de tratamento associadas com nível aumentado de eotaxina com 25-hidroxivitamina d3
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
BR112013027403A2 (pt) composições que compreendem uma antimetabólito de glicose e selênio
TWD163459S (zh) 錶用機心
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
AR082215A1 (es) Composicion farmaceutica agradable al paladar
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
BR112013018287A2 (pt) derivados monoterpenos de chalcona ou de diidrochalcona e sua utilização como agentes de despigmentação
ECSP13012603A (es) Nueva formulacion del cetp(1)
CL2012002079A1 (es) Compuestos derivados del alquil-6-arilsulfamoil-ciclohexen-carboxilato para suprimir un trastorno periferico inducido por agente anti-cancerigeno.
UA108126C2 (uk) Спосіб отримання співполімеру натрійкарбоксиметилцелюлози й госиполу
BR112013000506A2 (pt) núcleo absorvente
BR112012033437A2 (pt) núcleo absorvente